|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||138.63 - 143.00|
|52-week range||130.15 - 184.00|
|Beta (3Y monthly)||1.01|
|PE ratio (TTM)||16.60|
|Earnings date||25 Feb 2019 - 1 Mar 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||185.89|
Bruce Cozadd has been the CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) since 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, Read More...
Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017, which reflected ~17% YoY (year-over-year) growth. Defitelio reported net revenues of $111.7 million during the first nine months of 2018—compared to $97.4 million during the same period in 2017, which reflects ~15% YoY growth.
Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.
Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9. On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which is ~19% below its 52-week high of $184.00 on June 20.
Jazz Pharmaceuticals plc (JAZZ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Jazz Pharmaceuticals stock collapsed Wednesday after the drugmaker missed third-quarter expectations for cancer treatment Vyxeos and cut its guidance for 2018. Shares lost more than 10%.
Jazz Pharmaceuticals shares crumbled late Tuesday after the top-rated pharma stock missed sales expectations in the third-quarter and issued 2018 guidance that lagged analyst views.
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
Stock futures rose sharply on election results: Democrats won the House but the GOP held the Senate. Seven leaders were big stock market movers on earnings.
Jazz (JAZZ) delivered earnings and revenue surprises of 7.51% and -2.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had profit of $2.41 per share. Earnings, adjusted for asset impairment costs and stock option expense, were $3.58 per share. The results topped Wall Street expectations. ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
After Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) earnings announcement in June 2018, the consensus outlook from analysts appear somewhat bearish, with earnings expected to grow by 14% in the upcoming year relative Read More...
Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how toRead More...